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Summary A 4-day tumour sensitivity assay of potential use in predicting tumour response to cytotoxic drugs
has been investigated in patients with chronic lymphocytic leukaemia. The method comprised isolation of
white cells from peripheral blood, drug exposure and incubation'for 4 days. Drug-induced tumour cell kill
was assessed by differential staining of dead and live cells such that the latter could be morphologically
identified, with subsequent calculation of tumour cell viability. Concentrations of drug for use in the assay
were chosen for chlorambucil (2jugmlP1), 4-hydroperoxy-cyclophosphamide (2ygml1)--which was used in
vitro in place of cyclophosphamide-prednisolone (0.5pgml-') and vincristine (0.1IMgml 1), to give a scatter
of values which was in good agreement with clinical expectations. In 21 cases where the in vitro result could
be compared with the in vivo response, there were 4 true positive comparisons (sensitive in vitro, sensitive in
vivo), 15 true negative comparisons (resistant both in vitro and in vivo) and 2 false positive comparisons
(sensitive in vitro, resistant in vivo). A result was obtained in 86% (65/76) of samples received. The assay
appears to show considerable promise as a tumour chemosensitivity test and warrants wider investigation,
including prospective in vivo/in vitro correlations that could be based on the results presented here.
Since the 1950s, many investigators have tried to
develop in vitro tests to predict the response of
individual tumours to chemotherapy (for reviews,
see Dendy, 1976; Von Hoff & Weisenthal, 1980;
and Hamburger, 1981). Of greatest interest in
recent years have been the so-called tumour colony
forming or stem cell assays (Courtenay & Mills,
1978; Hamburger & Salmon, 1977; Salmon et al.,
1978, 1980; Von Hoff et al., 1981). However,
although these assays have a relatively sound
theoretical basis, there are a number of practical
difficulties: they are very time consuming; results
can only be obtained from 25% of samples tested
(Von Hoff et al., 1981); and some types of tumour
cannot be tested at all.
Other methods that have been used include
assays based on radioactive precursor incorporation
(e.g. Volm et al., 1979; Group for sensitivity testing
of tumors (KSST), 1981) and dye exclusion (e.g.
Durkin et al., 1979). These methods have not been
as widely accepted, partly on account of the fact
that a specific effect in the tumour cells could be
masked by large numbers of non-tumour cells since
both populations are assayed together.
Recently Weisenthal et al. (1983a,b, c) have
reported a dye exclusion assay where, after 4 days
incubation, live tumour cells can be stained,
identified cytologically and enumerated separately
from dead cells and non-tumour cells, thus
constituting what could be termed a "tumour cell
killing assay."
This assay has a number of advantages over
other in vitro assays. It is simple, reproducible and
has been applied to a broad spectrum of tumour
types (Weisenthal et al., 1983a,b). The assay (along
with a similar assay incorporating duck red blood
cells as an internal standard) compares favourably
in both drug sensitivity and accuracy of clinical
correlations with a standard colony forming assay
(Weisenthal et al., 1983a, c). Weisenthal et al. (1983c)
also suggest that "dye exclusion tests may be
specially valuable in assessing drug-induced
cytotoxicity in non-dividing cells". For this reason,
we have investigated the use of this dye-exclusion
assay with samples from patients with chronic
lymphocytic leukaemia (CLL) and have attempted
to define a system by which future predictive in
vivo/in vitro correlations could be determined.
Materials and methods
Drugs
Prednisolone (Codelsol; Pred) and vincristine
(Oncovin; Vc) were obtained as drugs for injection.
Chlorambucil (4-{p-di(2-chloroethyl)-aminophenyl}
butyric acid; Chl) was a gift from Burroughs
Wellcome, Beckenham, Kent. 4-Hydro-peroxy-
cyclophosphamide (4-Cy) (kindly donated by
Boehringer Ingleheim, Bracknell, Berks.) was
used in vitro in place of cyclophosphamide
(Cy) because of the inactivity of the latter in vitro.
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Drugs were made up in PBS and stored at
-40°C at 10 times the final concentration used for
the assay.
Stains
Fast green (C.I. 42053, Sigma Chemical Co. Ltd.)
was made up at 2% (w/v) in RPMI medium with
or without foetal calf serum (see below) and filtered
to 0.2,um to remove any particulate matter.
Modified haematoxylin was made by adding 2%
(v/v) glacial acetic acid to Harris Haematoxylin
(Ortho modification, Ortho Diagnostics, High
Wycombe, Bucks., U.K.) and filtering the solution
before use. A 1% (w/v) stock solution of eosin Y
(C.I. 45280; B.D.H., Poole, Dorset) was made in
95% (v/v) ethanol, and a 1% (w/v) stock solution
of phloxine B (C.I. 45420, B.D.H.) was made up in
water. The modified eosin solution was made up by
mixing stock eosin Y, stock phloxine B, 95%
ethanol and glacial acetic acid in the ratio
50: 5: 390: 2 (v/v/v/v).
Trypan blue (C.I. 23850: B.D.H.) was made up
at 0.2% in PBS and was routinely used to
determine cell viability on wet preparations in a
haemocytometer. Fluorescein diacetate (Aldrich
Chemical Co., Ltd., Gillingham, Kent) was made
up at 5mgml-1 in acetone, diluted to 5jgmlP' in
PBS and used at a final concentration of about
1 pgml-'.
Patients
Blood was obtained from patients who were
attending the hospital on an out-patient basis. Most
were chosen because they were already undergoing,
or were about to start, chemotherapy for their
CLL. Diagnosis of CLL was based on the
demonstration of a peripheral blood lymphocytosis
and histological examination of bone marrow
(5cases) or lymph node (5 cases) or both (3 cases).
In one patient presenting with stage I disease,
splenomegaly and thrombocytopenia developed
gradually over 2 years. One patient was referred to
the hospital and diagnostic criteria were not
available. Patients were staged according to the
method of Rai et al. (1975).
Patients 1, 2, 3, 5, 10, 13 and 15 had received no
cytotoxic drugs before the therapy with which a
correlation was obtained, whereas the other patients
had received chemotherapy for 1-6 years
previously. Patients received 4-weekly courses of
prednisolone (40mg for 5 days) either alone or in
combination with chlorambucil (20-30mg for 2
days) or cyclophosphamide (200-300mg for 4 days)
sometimes including vincristine (2mg i.v.). At least
3 months treatment was given before an assessment
of response was made.
Clinical response was assessed by the criteria of
Rai et al. (1975). Patients achieving a complete or
partial remission were taken to be sensitive for
purposes of comparison with in vitro sensitivity,
while those showing only clinical improvement or
no-response were termed resistant.
As this work was mainly involved in setting up
the assay system, most of the time it was not
possible to evaluate the patients in ignorance of the
in vitro result or vice versa.
Cell separation
Blood (5-10ml) was collected into lithium heparin
or potassium EDTA tubes and then layered onto
Lymphocyte separation medium (LSM; Flow
Laboratories, Irvine, Scotland) for separation of the
whole white cell population at 1 g. The cells
remaining at the LSM interface were collected,
washed twice and finally suspended in RPMI-FCS
medium (RPMI 1640 medium containing 10%
foetal calf serum, 20mM HEPES (N-2-
hydroxyethylpiperazine-N'-2-ethanesulphonic acid),
2mM glutamine, 0.125pgml-1 fungizone (all from
Flow Laboratories) and 40pgml-' gentamycin).
They were counted and tested for viability using
trypan blue. The cell preparations obtained by this
procedure were consistently 99% viable.
Drug treatment
Cells were diluted to S x 105 ml-1 and 450M1 placed
in sterile polystyrene tubes. Drugs were added in
5Opul PBS to triplicate tubes. Twelve controls
received 50pl PBS. Vc and Pred were left in for the
entire 4-day period of the assay, whereas Chl and
4-Cy were removed after 1 h. To achieve this, cells
were twice washed with 5ml of FCS RPMI
medium, centrifuged at 400g for 5min, and finally
resuspended in 0.5ml of fresh medium. This
reduced the drug concentration to a calculated
0.1% of the original value. Six controls (for Chl
and 4-Cy) received the washing procedure, the
other 6 controls (for Vc and Pred) were not
washed.
Staining ofcells
All control and drug-treated tubes were incubated
at 37°C for 4 days (a convenient time chosen by
Weisenthal et al., 1983c). After this 0.5ml of 2%
fast green dye solution was added to each tube,
which was briefly agitated with a whirlimix. The
dye stains membrane permeable cells but is
excluded by intact cells. After about 8min at room
temperature, samples were whirlimixed again,
vigorously agitated with a pasteur pipette and
loaded into cytocentrifuge chambers at -105 cells
per chamber. At 12min the samples wereSHORT TERM TUMOUR CHEMOSENSITIVITY ASSAY 783
cytocentrifuged onto ethanol-washed slides at
1,250rpm for 7min and air dried.
Slides were counterstained through a series of
solutions: modified haematoxylin (90sec), 4 changes
of 7.5% ethanol to lyse red blood cells (2 quick
dips each), modified eosin (30sec) and 2 quick dips
in each of 2 changes of 95% ethanol, absolute
ethanol and xylene. Slides were then mounted with
Eukitt mountant. With this procedure fast green
stained cells retained the green colouring while live
cells were counterstained with the haematoxylin
and eosin.
Live cells were identified by standard
morphological criteria (see Figure 1c). It was not
possible to identify the dead cells as all
morphological features had been lost, but this did
not affect the calculations of tumour cell viability
(see below).
Cell counting and calculation
Three categories of cells were counted on the slides:
live tumour cells (NLT; i.e. number of live small
lymphocytes), live normal cells (NLN; i.e. number of
live non-tumour cells) and dead cells (ND; i.e. fast
green stained cells) (see Table II), and the
percentage of live tumour cells (LT) calculated:
LT= NLT x 100.
NLT+NLN+ND
The proportion of tumour cells still alive after drug
treatment (tumour cell viability, TCV) was then
calculated as a percentage ofcontrol:
TCV= LTdrugtreated x 100.
LTcontrol
Except where very low viabilities were encountered
(<11%), 50 live tumour cells were counted on each
of the slides made from the triplicate
determinations. Where dead cells greatly
outnumbered live tumour and live non-tumour cells
(viability <10%) one tenth of the dead cells in
each field was counted using a counting grid and
Figure 1 (a) Cells after fast green staining and
cytocentrifugation. Dead cells (D) have stained blue-
green whereas live cells (L) have excluded the dye.
Bar= 50gm. (b) Cells from Figure 1(a) after
haematoxylin and eosin counterstaining. The dead cells
are still blue-green, and the lighter live cells are stained
pink. The cells have shrunk slightly and lost the halo
of fast green. Specks of fast green and other debris are
usually washed off by the counterstaining process.
Bar=50jgm. (c) High magnification showing typical
morphology of granulocytes (LN) and small
lymphocytes (LT). The dead cell shows an absence of
morphological detail. Bar=10 IOm.784 A.G. BOSANQUET et al.
the resulting number of dead cells multiplied by 10
before calculating the LT.
Where drugs were given in combination in vivo,
the lowest in vitro result (minimum TCV) of the
drugs in the combination was used for comparison
with clinical response.
Results
Figure a shows cells on a typical microscope slide
after fast green staining and cytocentrifuging. The
fast green stains dead cells blue green, easily
distinguished from occasional dust or dye particles
which are bright green in colour, whilst live cells
exclude the dye. Figure lb shows the same
microscope field after counterstaining. The dead
cells have retained their green colour whilst the live
cells (mostly small lymphocytes) are stained purple
and pink with the haematoxylin and eosin.
Comparison of Figures la and lb shows that,
although cell shrinkage sometimes occurs on
counterstaining, very few, if any, of the cells are
lost during the procedure. Further careful analysis
of a number of fields before and after
counterstaining confirmed this with only 2 cells lost
out of -900 counted. Figure Ic shows the
morphological integrity of the live cells that is
obtained with this staining procedure.
Table I gives the results of counting a number of
slides made from patient 13. The figure for Vc
illustrates a typical low viability count.
Methodological checks
Equal-sized aliquots of the same sample of cells
were sometimes found to produce different densities
of cells on the slide. Thus a number of experiments
were performed to check that the result of the
cytocentrifugation and staining procedures
accurately reflected the cell population in the tube.
Isolated white cells from 2 patients were killed by
heating at 60°C for 4h and mixed with the original
live cells to give -0, 25, 50, 75 and 100% live cells.
Viability was then determined by fast green staining
and haematoxylin and eosin counterstaining as
detailed above. The good correlation between
observed and expected values (r>0.996) shown in
Figure 2 confirms that the procedure does preserve
and differentiate live and dead cells in a mixed
population. This was further confirmed by staining
replicate samples of the 50% live mixture from one
such experiment with fast green (cytocentrifuged
and counterstained as normal), fluorescein diacetate
(which stains live cells) and trypan blue. The LT
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Figure 2 Percentage of live cells observed after
staining known proportions of live and dead cells with
fast green. Cells were killed by heating to 60°C for 4h.
Four different experiments using cells from two
patients are shown here. r>0.996
Table I Typical cell counts made from microscope slides (Patient 13). The percentages of live tumour cells (LT)
and tumour cell viability (TCV) are also shown
No. ofcells counted
No. ofslides
Sample counted NNT NLN NDt LT(%) TCV(%)
Control (for Chl and 4-Cy) 3 191 0 150 56.0 100
Chl (2ygmlP') 3 123 0 640 16.1 28.8
4-Cy (2pgml-') 3 150 0 317 32.1 57.4
Control (for Pred and Vc) 6 393 2 243 61.6 100
Pred (500ngml -1) 3 144 1 226 38.8 63.0
Vc (lOOngml-') 3 161 3 3,080* 5.0 8.1
*Actually counted the dead cells in 1/10th of each microscope field using the counting grid (308 cells) and then
multiplied by 10.
tD refers to all dead cells, both tumour and non-tumour.
'°°r-
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values in these cases were 47.6, 44.3 and 46.6%
respectively.
In another experiment to check that fast green
stains dead cells, cells from 5 patients were put
through the assay as normal, and after 4 days
stained with both fast green and fluorescein
diacetate. On average 98.5+ 1.9% (mean+s.d.,
n=30 control and drug treated samples) of cells
stained with one of the two dyes and no cells
stained with both.
These results suggest that under the conditions of
the assay fast green accurately differentiates dead
cells in both control and drug-treated cultures, and
that LT values are not affected by loss of cells in
the cytocentrifuging process.
Two major problems with dye exclusion assays
are cell proliferation and autolysis and if these
occurred, both of them would artificially increase
the LT. In CLL, however, cell proliferation is
<1% (Tannock, 1978). To determine the extent of
autolysis in the present assay, control and drug-
treated samples from 5 patients were counted at
the beginning and end of the experiment. The
average cell loss was only 1.2% (s.d. =6.8%,
n=30). No significant differences were found in
the cell loss between control and drug-treated
samples over the 4 days of the study.
Optimisation ofculture conditions
Experiments were performed to determine
important factors in obtaining the best control
viabilities and cell morphologies. The whole assay
was undertaken with media containing different
types of serum, and different media were used in
the cell washing procedure (at the end of 1 h drug
incubations) and for dissolving the fast green stain.
Control viabilities in the assay using RPMI-
FCS medium were little different whether the
serum was heat-inactivated prior to use (LT=
30.7+23.5%, mean+s.d.; n =74 samples from
different patients) or not (22.9+19.7%; 31).
Replacement of the FCS by the patient's own
(autologous) serum at a final concentration of 10%
also had no effect on control viability (34.1 +23.9%;
10). Collection of blood into potassium EDTA
increased control viabilities (LT=41.3+ 20.0%; 39).
In addition <5% of samples had a control viability
of < 10%, compared with 18% when blood was
collected into lithium heparin tubes. Control
viabilities were similar whether round- or flat-
bottomed polystyrene tubes were used
(LT=31.7±24.5%; 55 and 27.3+21.4%; 18).
When 1 h drug incubations were performed, the
cells were washed with two 5ml aliquots of medium
to remove residual drug. Best viabilities and cell
morphologies at the end of the assay were obtained
when cells were washed with RPMI-FCS medium.
Washing with either PBS or RPMI medium
containing 10% newborn calf serum tended to
reduce the cell viability and resulted in some cell
ghosting.
Fast green dissolved in RPMI-FCS medium gave
better morphology and viability than dissolving the
dye in PBS according to Weisenthal et al. (1983a).
Difficulty was experienced, however, in filtering the
fast green solution, and so, as fast green dissolved
in serum-free RPMI medium gave equivalent results
and filtered easily, it was used routinely in the
assay.
Drug concentrationsfor use in vitro
Drug concentrations for use in vitro to predict for
in vivo response were determined empirically to give
the most accurate comparison with clinical response
(as with other in vitro assays). First, an estimate of
the possible range of drug concentrations was
obtained from in vitro methods already published
(Salmon et al., 1978; Von Hoff et al., 1981;
Weisenthal et al., 1983a) or from pharmacological
parameters such as concentration times time values
(Nelson et al., 1980; Bosanquet & Gilby, 1982;
Alberts & Chen, 1980). Up to 5 different
concentrations based on these figures were then
used in the assay when the drug was first
investigated.
Typical dose-response curves are shown for Chl
in Figure 3. Final drug concentrations were chosen
100
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Figure 3 Values of TCV after exposure of patients'
cells to 1 to 10pgml 1Chl. Each line represents a
different patient.786 A.G. BOSANQUET et al.
from the dose-response curves which gave a scatter
of results in accordance with clinical experience of
response (Desai et al., 1970; Han et al., 1973;
Liepman & Votaw, 1978; Oken & Kaplan, 1979;
Sawitsky et al., 1977) using a sensitive/resistant cut-
off of 30% TCV. The results of the assays
performed using these drug concentrations
(2ygml-1 for Chl and 4-Cy, 0.5pgml-1 for Pred
and 0.1 ugml - 1 for Vc) in a larger series of
patients are shown in Figure 4. These same drug
concentrations were used for comparison with
clinical response in vivo in 15 patients receiving
chemotherapy.
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success of the assay was 100%, and this included
repeat assays of the previous 3 patients whose cells
were non-viable after 4 days in culture.
Assays were often performed on cells taken from
the same patient on consecutive visits to the
hospital. In most cases the values of TCV obtained
were remarkably similar over a period of several
months. We are continuing to monitor the in vitro
chemosensitivity of the responsive patients, to
determine whether loss of in vitro sensitivity will
predict for relapse in vivo.
Table II gives the clinical details of the patients
whose response was compared with in vitro
chemosensitivity and Table III shows the details of
these comparisons. The comparison was prospective
(i.e. in vitro test performed just prior to each new
drug schedule) in all cases except in patients 2, 6a,
9, 11 and 12 where the earliest successful in vitro
assay result was used. It can be seen from Table III
that the minimum TCV of the drugs the patients
received agrees well with the in vivo response.
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Figure 4 Values of TCV for single drugs. Each point
represents a different patient. Drug concentrations
used were 2 ugml-1 (Chl and 4-Cy), 0.5pgmm1 (Pred)
and 0.1 jugml-' (Vc).
Assay results
From 10-50 tubes were set up for each patient for
different controls, drugs and drug concentrations.
At no time was the number of cells a limiting
factor. The assay was technically successful (i.e. at
least 4 drugs or drug concentrations could be
successfully counted at the end of the assay) in
86% of samples received. Eleven of 76 (14%)
assays performed were not successful for the
following reasons: setting-up errors (2); staining
errors (4); bacterial contamination (2) and no viable
cells after 4 days in culture (3). When blood was
collected into potassium EDTA, the technical
Discussion
The 4-day tumour cell chemosensitivity assay
described in this paper avoids a major pitfall
associated with other short term (i.e. <7 day) in
vitro assays (for review see Von Hoff & Weisenthal,
1980) in that it measures kill of tumour cells
specifically as distinct from that of both tumour
and non-tumour cells. At the same time it does not
have the technical limitations of the "stem cell" or
"cloning" assays, which are time consuming, and
only work in -25% of specimens received (Von
Hoff et al., 1981). Thus, although the stem cell
Table II Details of patients on whom an in vitro/in vivo
comparison was obtained
Disease Clinical
Patient history stage when
No. Sex Age (months) assayed
1 M 59 26 I
2 M 58 36 II
3 F 70 44 II
4 F 78 62 II
5 M 74 3 IV
6 M 69 43 III
7 M 69 32 IV
8 F 64 84 III
9 M 53 97 II
10 M 78 8 IV
11 M 77 68 IV
12 F 60 168 III
13 M 76 3 IV
14 F 73 200 IV
15 M 79 3 II
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Table III Comparison of results of the in vitro assay with in vivo response
In vitro assay result (TCV; %)
Drugs given Minimum Response
Patient Chl 4-Cy Vc Pred in vivo TCV(%)* in vitrot/in vivo
la 31 10 103 70 Cy, Pred 10 S/S
2 30 34 33 12 Cy, Vc, Pred 12 S/S
3 13 21 15 24 Cy, Vc, Pred 15 S/S
lb 18 2 75 106 Chl, Pred 18 S/S
4 26 28 43 51 Cy, Vc, Pred 28: S/R
5a 28 53 39 50 Chl, Vc, Pred 281 S/R
6a 80 31 55 81 Cy, Vc, Pred 314 R/R
5b 39 61 33 71 Cy, Vc, Pred 33: R/R
7 100 31 31 78 Chl, Vc, Pred 31 R/R
8 40 63 6 32 Pred 32 R/R
9 83 90 62 32 Cy, Vc, Pred 32 R/R
10 52 66 38 68 Chl, Vc, Pred 38 R/R
11 46 68 40 42 Chl, Pred 42 R/R
12a 102 96 37 42 Chl, Pred 42 R/R
b 102 96 37 42 Cy, Pred 42 R/R
13 29 57 8 63 Pred 63 R/R
14a 86 96 60 70 Chl, Pred 70 R/R
b 86 58 41 72 Pred 72 R/R
15 74 87 66 73 Pred 73 R/R
Ic 24 9 72 78 Pred 78 R/R
6b 80 31 55 81 Chl, Pred 80 R/R
*This value is the lowest in vitro assay result for the drugs given in vivo.
tIn vitro response is based on a sensitive (S)/resistant (R) cut off of minimum TCV=30%.
$These patients achieved a clinical improvement in response to the treatment shown.
assay is a highly sensitive test of tumour
chemosensitivity, its major role increasingly seems
to be in the area of preclinical antineoplastic drug
screening (Weisenthal, 1981; Salmon et al., 1981).
By contrast, tumour cell assays measure the
proportion of all tumour cells killed. Thus, whilst
stem cell assays may be capable of predicting
potential tumour cure, tumour cell assays may
correlate more satisfactorily with tumour response
as observed by the clinician.
Problems associated with dye exclusion assays
We have followed the timing of Weisenthal et al.,
(1983a,c) using a 4-day incubation period for the
assay to allow for drug-damaged cells to become
membrane permeable whilst avoiding excessive loss
of control viability. During the 4 days, both cell
proliferation and autolysis could occur but while
these may present problems for other tumour
systems, both are minimal for CLL using the
present assay.
Since the loss of membrane integrity is a late
event in cell death, this assay may require higher
drug concentrations than the stem cell assay to
achieve equivalent cell kills (Wiesenthal et al.,
1983c). This difference in sensitivity and the time
required for loss of membrane integrity have been
largely ignored in work attempting to correlate and
compare the 2 types of assay (Roper & Drewinko,
1976, 1979; Bhuyan et al., 1976). This has led to the
clearly erroneous conclusion that dye exclusion
assays are inappropriate to measure drug-induced
cell kill (Roper & Drewinko, 1979).
One other potential problem with the present
assay is that some lethally-damaged cells may take
longer than 4 days to lose their membrane integrity
and the extent to which this occurs may differ for
each drug. However, for each drug a number of
samples have shown good sensitivity, indicating that
with the drug concentrations used, many of the cells
have lost their membrane integrity by 4 days. In
addition, no patients who have shown in vitro
resistance have been sensitive in vivo indicating
again that delayed death is not a major problem.
One problem common to all in vitro
chemosensitivity assays is that of drug activity in
vitro. Following Volm et al. (1979), we have used 4-
hydroperoxycyclophosphamide (4-Cy) in vitro to
predict for Cy in vivo. It is very active in vitro
(requiring only 2ygml-1) probably due, unlike the
situation in vivo, to little of the 4-Cy being
degraded to inactive metabolites.788 A.G. BOSANQUET et al.
Comparisons with in vivo response
Considerable problems arise in the attempt to
compare in vitro and in vivo data when the in vivo
results are obtained with combination
chemotherapy. Because of this, different authors
have used different criteria in the assessment of true
and false correlations of response (Salmon et al.,
1978; Weisenthal et al., 1983a, Von Hoff et al.,
1981). Previously, in a preliminary report of this
work, we investigated the use of the TCV averaged
over the drugs given in vivo (Bosanquet et al., 1982)
but here we have used the criteria of Von Hoff et
al. (1981) requiring only one drug of a combination
to be sensitive in vitro for comparison with the
response in vivo. Using these criteria, it is essential
that all the drugs given in combination to the
patient are tested in vitro and we have only
attempted a comparison when this condition is
fulfilled. As with most other studies we have used a
cut-off between sensitive and resistant of 30%
TCV, which gave us 2 false positive comparisons
(sensitive in vitro, resistant in vivo). This is higher
than the value which would give us no false
comparisons (25% TCV, see Table III) but is
preferable to the higher probability of false negative
comparisons being obtained with this lower cut-off.
With the inherent errors in any in vitro assay, a
definite cut-off line between sensitivity and
resistance is likely to be of less value clinically than
some form of graded probability of response. Thus
we would say (Table III) that any TCV below
-25% would predict for partial or complete
response, whereas a value greater than -35%
would most likely show no response or progressive
disease despite chemotherapy. Intermediate values
would most likely predict for clinical improvement.
The administration of drug combinations to
patients who respond will always mean that it is
never known which of the drugs has been active in
vivo. However, if the in vitro results are shown to
predict responsiveness accurately, then this lack of
precise knowledge need not be a major limitation.
We have shown that the assay described here is a
technically feasible approach to the in vitro
determination of chemosensitivity in CLL and that
this is in concordance with clinical response.
Including the work of Weisenthal and colleagues
(1983a,b) there are now 69 in vitro/in vivo
comparisons or correlations of which only 4 are
false (all sensitive in vitro, resistant in vivo). This
compares very favourably with results obtained by
the stem cell assay and suggests that this dye
exclusion could be of considerable value in the
prediction of tumour chemosensitivity. In addition,
the assay is rapid, relatively simple to perform
and requires small numbers of cells. We conclude,
therefore, that this assay warrants wider
investigation for the prediction of tumour chemo-
sensitivity. To this end, we are now assessing the
assay and its modified form (Weisenthal et al.,
1983c) in a broader spectrum of tumour types
using both phase- and cycle-specific drugs. We are
also attempting to define optimum levels of
VP-16-213, nitrogen mustard (HN2),
1-(2-chloroethyl)-cyclohexyl-l-nitrosourea (CCNU)
and 2-deoxycoformycin for use in CLL.
We would like to thank the Leukaemia Research Fund for
generously supporting this work, Ms. M. Brannan for
technical assistance and Ms. C. Henderson for typing the
manuscript.
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